Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Oral Ozempic and the Risks of Compounding Formulas
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, explore major updates in the evolving GLP-1 receptor agonist landscape, with a particular focus on oral semaglutide formulations, branding changes, and regulatory concerns surrounding compounded alternatives.Key Episode Timestamps00:00:01 Intro00:00:25 Oral Wegovy and oral Ozempic00:03:04 Why Rybelsus didn't work00:05:33 The importance of administration00:06:56 Compounding drugs - the Hims and Hers drama00:07:56 The danger of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.